Fortimedix has been acquired by Medtronic
November 2024 — Fortimedix Surgical has been successfully acquired by Medtronic (NYSE: MDT). Following the transaction, Fortimedix will operate as Medtronic Articulating Technologies.
Located at the Brightlands Chemelot Campus in Geleen, the Netherlands, Fortimedix operates a fully equipped R&D and pilot manufacturing facility that allows the seamless integration of product development and pilot manufacturing under a single roof.
Our role in the transaction
Oaklins’ team in the Netherlands acted as the exclusive sell-side M&A advisor to Fortimedix in its sale to Medtronic. This transaction underscores Oaklins’ strong international track record in the medical technology sector, demonstrating their ability to unlock significant value in a rapidly evolving, innovation-driven industry. Leveraging deep sector expertise and a global network of strategic buyers, the team ensured a smooth and successful transaction process for all parties involved.
Wout Bijker
CEO, Fortimedix Surgical
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more